JP2023548083A - セリアックスプルー病を治療するための組成物及び方法 - Google Patents

セリアックスプルー病を治療するための組成物及び方法 Download PDF

Info

Publication number
JP2023548083A
JP2023548083A JP2023525049A JP2023525049A JP2023548083A JP 2023548083 A JP2023548083 A JP 2023548083A JP 2023525049 A JP2023525049 A JP 2023525049A JP 2023525049 A JP2023525049 A JP 2023525049A JP 2023548083 A JP2023548083 A JP 2023548083A
Authority
JP
Japan
Prior art keywords
amino acid
seq
polypeptide
acid sequence
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023525049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548083A5 (https=
Inventor
プルツ，イングリッド，スワンソン
ウルフ．クランシー
シーゲル，ジャスティン，ブルームフィールド
ティンバーグ，クリスティーン，イレイン
スチュワート，ランス
ベイカー，デイビッド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2023548083A publication Critical patent/JP2023548083A/ja
Publication of JP2023548083A5 publication Critical patent/JP2023548083A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/488—Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2023525049A 2020-10-30 2021-10-29 セリアックスプルー病を治療するための組成物及び方法 Pending JP2023548083A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063108163P 2020-10-30 2020-10-30
US63/108,163 2020-10-30
PCT/US2021/057197 WO2022094177A1 (en) 2020-10-30 2021-10-29 Compositions and methods for treating celiac sprue disease

Publications (2)

Publication Number Publication Date
JP2023548083A true JP2023548083A (ja) 2023-11-15
JP2023548083A5 JP2023548083A5 (https=) 2024-11-06

Family

ID=78819631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023525049A Pending JP2023548083A (ja) 2020-10-30 2021-10-29 セリアックスプルー病を治療するための組成物及び方法

Country Status (12)

Country Link
US (1) US20250064903A1 (https=)
EP (1) EP4237554A1 (https=)
JP (1) JP2023548083A (https=)
KR (1) KR20230093323A (https=)
CN (1) CN116829166A (https=)
AR (1) AR123961A1 (https=)
AU (1) AU2021368118A1 (https=)
CA (1) CA3195929A1 (https=)
CO (1) CO2023006731A2 (https=)
MX (1) MX2023004807A (https=)
TW (1) TW202233834A (https=)
WO (1) WO2022094177A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068987A1 (en) 2023-09-28 2025-04-03 Takeda Pharmaceutical Company Limited A method of producing a kumamolisin-as polypeptide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000178297A (ja) * 1998-10-05 2000-06-27 Takeda Chem Ind Ltd Ｎ末端メチオニンの除去方法
JP2018517409A (ja) * 2015-06-08 2018-07-05 ユニヴァーシティ オブ ワシントン セリアックスプルー病を治療するための組成物および方法
JP2020505944A (ja) * 2016-12-22 2020-02-27 イーダブル ニュートリション ゲゼルシャフト ミット ベシュレンクテル ハフツング 安定なプロテアーゼ変異型

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882502A1 (en) 2011-08-10 2013-02-14 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease
US10266815B2 (en) * 2013-08-14 2019-04-23 University Of Washington Through Its Center For Commercialization Compositions and methods for treating celiac sprue disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000178297A (ja) * 1998-10-05 2000-06-27 Takeda Chem Ind Ltd Ｎ末端メチオニンの除去方法
JP2018517409A (ja) * 2015-06-08 2018-07-05 ユニヴァーシティ オブ ワシントン セリアックスプルー病を治療するための組成物および方法
JP2020505944A (ja) * 2016-12-22 2020-02-27 イーダブル ニュートリション ゲゼルシャフト ミット ベシュレンクテル ハフツング 安定なプロテアーゼ変異型

Also Published As

Publication number Publication date
EP4237554A1 (en) 2023-09-06
AU2021368118A9 (en) 2023-07-06
CA3195929A1 (en) 2022-05-05
TW202233834A (zh) 2022-09-01
AR123961A1 (es) 2023-01-25
MX2023004807A (es) 2023-05-10
US20250064903A1 (en) 2025-02-27
AU2021368118A1 (en) 2023-05-11
WO2022094177A1 (en) 2022-05-05
CN116829166A (zh) 2023-09-29
KR20230093323A (ko) 2023-06-27
CO2023006731A2 (es) 2023-06-09

Similar Documents

Publication Publication Date Title
JP6502428B2 (ja) セリアックスプルー病を治療するための組成物および方法
JP6764555B2 (ja) セリアックスプルー病を処置するための組成物および方法
KR102702879B1 (ko) 셀리악 스프루 질환 치료용 조성물 및 방법
JP2023548083A (ja) セリアックスプルー病を治療するための組成物及び方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241028

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241028

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331